Ad Narrator | Sourcery Summary

1. Key Themes

Healthcare Is the Hero Use Case for AI Outside Silicon Valley

Nworah Ayogu argues healthcare is where AI reaches the general public, and that OpenAI has quietly become a mass-scale health provider. He frames the consumer behavior as universal. "OpenAI is now one of the largest healthcare providers in America. They have 300 million people asking ChatGPT questions every week about healthcare specifically." 00:00:53 He sharpens the point later: "healthcare is the key hero use case for most people, right? For Silicon Valley, it's coding. For the rest of America, it is healthcare." 00:00:53 His evidence is a partnership with Boston Children's and Harvard hospitals: "They were able to get to new diagnoses for about kind of 20 of them" out of roughly 300 unsolved pediatric cases. 01:07:52

The Bottleneck Shifts Down the Value Chain, So Invest Across It

Ayogu's recurring framework is that when one step gets 10x better, the constraint moves downstream (to testing, clinical trials, manufacturing, commercialization), and that value flows through the whole supply chain as it did in AI. "The same way that with AI... we've seen that trade flow through the entire supply chain: needs around compute, needs around memory, needs around kind of energy... We're going to see the same thing with, you know, biotech, where it's not just drug discovery. It's going to be manufacturing... clinical trials... commercialization." 00:02:19 On the Isomorphic Labs goal of a 90% success rate: "What we don't want to do is get very good at the sort of pre-clinical, and still have the clinical be the bottleneck." 00:09:03 And: "If we're going to be in a world where we can have new drugs coming out, you know, every sort of 3 years rather than every 10 years, that also means our manufacturing processes have to get better and faster."

AI Drug Discovery's Real Frontier Is Predicting Biological Effects, Which Is a Data-Generation Problem

Ayogu explains that binding a target is increasingly solved, but predicting downstream effects and side effects is not, because unlike code, biology isn't instantly verifiable. "With coding, with math, you know, those things are very verifiable. So I know whether my code compiles or not... For these things, I have to also verify, did my molecule work?" 00:04:29 He adds that "before the models can predict how well what effects it'll have, we have to have enough data to train them to make those predictions. And that's a bit of what you're hearing folks say when they say, we need to generate the data." 00:04:29 His line on animal models: "we've cured cancer in mice 50 times. So... if you want to cure your cancer, the best thing to do is to be a mouse." 00:04:29

"Bilingual" Companies and Vertical Integration Win

Thrive's selection philosophy is to back companies that are world-class in two disciplines at once. "We want companies that are bilingual... they speak two languages fluently." 00:11:54 At Isomorphic, "the AI researchers... are world class... The chemists and biologists who sit within Iso... are as good as the folks you would find at... a Lilly, a Pfizer, a Broad Institute." 00:11:54 At Neuralink, he points to the "Elon company" pattern of vertical integration: "we are going to kind of vertically integrate through all parts of our supply chain that are important. If it's important, it's mission critical, we need to have it in-house." 00:18:01

Hardware and Biotech Intersection Unlocks "Biblical" Treatments

"Two of our companies, Neuralink and sort of Fortell... they're almost biblical in proportion, right? The lame can walk. The mute can speak." 00:02:19 Neuralink's team spans hardware builders at "the same level of SpaceX and sort of Tesla," neurosurgeons, in-house pathologists, radiologists, and battery experts. 00:14:44 Fortell applies custom silicon to hearing, a problem tied to dementia risk.

The Biotech Market Is Larger and More Ambitious, So Expect More Trillion-Dollar Healthcare Companies

Ayogu gives three reasons. First, macro demand: "If you take AGI to the extreme, we all are going to want more time... the things we know will be increased buckets will be healthcare... and then, you know, some version of kind of entertainment." 00:33:50 Second, existing scale: "Keytruda's 2025 revenue of just that one drug was larger than the revenue of you know, all the major labs combined." 00:35:12 Third, expanded surface area: "AI makes it easier to build, so companies are doing science and manufacturing, science and more of the care delivery, which... makes their businesses more defensible, but it also gives them a much bigger TAM." 00:38:51 His summary: "our problems haven't gotten smaller, right? The tools we have have gotten bigger." 00:39:48

Lilly's Win Over Novo Was an Operations Story, Not Just a Science Story

Ayogu uses GLP-1s as proof that innovating across the value chain wins. "Lilly leaned into its manufacturing and manufacturing capabilities... a year before Novo could unblock their supply, Lilly got there a year beforehand." 00:38:14 He adds that Lilly's direct-to-consumer move mattered too: "we all know kind of LillyDirect, they're able to say, 'Sure, we're a pharma company, but let's think in an innovative way around how we partner, and how we lean into kind of care delivery,' and they unblock that commercial aspect." 00:38:37

Incumbents Are Not Flat-Footed, So Expect Acquisition and Adjacency Moves

"The AI wave has also pushed incumbents to compete in a way they haven't before... Lilly launched Tune Therapeutics with NVIDIA... incumbents aren't flat-footed in the age of AI, and they're going to either try to build or buy the capabilities they need." 01:02:06 He cites McKesson as a lane-shifter: "McKesson has gone out and bought large oncology providers... That is a new thing that we hadn't seen before." 01:03:50

The US Healthcare System Is Huge, Expensive, and Failing on Outcomes

Ayogu supplies the numbers: "We spend $5 trillion a year now... projected to go to $9 trillion by the end of the decade... 20% of all jobs are healthcare jobs... It's the largest line item in the federal budget, six times the size of defense." 00:46:37 On outcomes: "for the last 10 years, we've spent about $40 trillion on healthcare, we have not moved our life expectancy an inch. And if that is not an indictment of the failure of the healthcare system, I don't know what is." 00:50:07

N-of-1 Medicine Is Here, and the New Constraint Is Cost

He uses Baby KJ, treated at Penn for a rare ammonia-processing disorder, as the canonical example. "They actually designed a custom treatment to gene edit that baby um right after birth... The baby now is 2 years old, walking, talking." 00:52:11 The cost: "$1.5 million to actually make the treatment and deliver it." 00:53:02 His follow-on question: "What infrastructure needs to exist to make that more scalable and more repeatable and cheaper?" 00:54:12

2. Contrarian Perspectives

Neuralink Is a More Interesting Company Than SpaceX

Ayogu volunteers this as one of his "hot takes," and Molly pushes back with the $3 trillion SpaceX framing. His reasoning is that the brain is the substrate for everything else: "I actually think of, you know, I think Neuralink is a more interesting company than SpaceX. The brain is vaster than space." 00:19:53 He continues: "We don't make it to space, we don't even invent silicon chips without our brain... the brain is still a more efficient engine of compute than, you know, every um every chip that NVIDIA has ever made." 00:20:53

If You're Truly AGI-Pilled, You Should Be Long Healthcare

Most AI bulls look at compute, models, and apps. Ayogu argues the second-order beneficiary is healthcare and entertainment, because abundance converts into demand for time. "If you're truly AGI-pilled, as they say, right, you should be actually long healthcare." 00:33:50 "We all are going to want more time, and we're going to want to be able to enjoy the time that we have." 00:33:50

Doctors Don't Hate Technology, They Hate Bad Technology

Conventional wisdom says physicians are slow adopters. Ayogu says the evidence of OpenEvidence contradicts it. "The thesis was always, 'Oh, you know, doctors just don't like technology.' It's like, 'Well, well no, because all the doctors have iPhones. They all have Macs at home. They just don't like the bad technology that they're forced to use all the time.'" 00:44:28 The proof is penetration: "Epic took 40 years to get to the scale it's at today, and Epic has less than 50% of physicians using their product after 40 years. OpenEvidence, after 3 years, got to 2/3." 00:45:39

AI-Doctor Is the Wrong Question, and the Integration Is the Product

Instead of "which is better, AI or doctor," Cadence reframed the problem. "They've decided, 'No, no, no. The real question is how do we integrate these two things so that everyone is doing what they're best for?'" 00:59:03 The AI learns each prescriber's patterns: "98% concordance with the prescriber and the doctor." 00:59:03

A New Health Insurer Was "Impossible," Until It Wasn't

Ayogu admits he told Thrive's founders in med school that Oscar couldn't work: "the last health insurer that was created was in 1977... You can't just build things." 01:04:31 The company then fell 95% from its December '22 peak and came back above its IPO price. His diagnosis is that a decade-old tech-first stack became an AI advantage. 01:05:21

3. Companies Identified

Isomorphic Labs

AI drug discovery company from Demis Hassabis, spun out of the DeepMind lineage. Mentioned as a model "bilingual" company with a 90%-success-rate ambition. Ayogu: "Iso and team invented protein folding with AlphaFold, right? That is why Demis got the Nobel Prize." 00:09:03 On culture: "they talk a lot about the Iso way and the fact that... they're actually bringing folks together to be able to do both, who are world-class." 00:11:54 Molly added that Demis wasn't raising when Josh Kushner pursued him. 00:11:54

Neuralink

Brain-computer interface company, a Thrive portfolio company. Mentioned for talent density, vertical integration, and results for paralysis and ALS patients. "They've created an implantable device that then lets these individuals interact and control a computer with their minds." 00:14:44 On hardware: "they're up to over a 1,000 of them" (threads), and "they actually created a separate robot to do the implantation." 00:14:44 On vertical integration: "I've never met a company before that insourced their own pathology lab." 00:14:44

Fortell

Hearing aid company, a Thrive portfolio company, founded by Matt DeJonge. Custom silicon plus semantic noise processing. "They all went out to TSMC and they taped out their own chips... It's unheard of to tape it out successfully the first time." 00:23:33 On rating: "4.5 was their highest rating that a hearing aid had ever gotten on their five-point scale. Fortell recently did it and got a six." 00:28:26 Demand is so high there's a waitlist, and Ayogu notes Steve Martin and Henry Kravis as users. 00:23:33

OpenEvidence

Clinical AI tool for physicians, a Thrive portfolio company. "2/3 of physicians in America are using OpenEvidence." 00:00:19 Ayogu said he first heard about it from residency friends and noted clinicians "rave" about it, unusual for health IT. 00:44:26

OpenAI

Thrive portfolio company. Mentioned for its healthcare footprint: "300 million people asking ChatGPT questions every week about healthcare specifically." 00:00:53 Ayogu helped organize meetings between OpenAI leadership and healthcare CEOs. 00:40:11

Cadence

Remote patient monitoring company with hardware, AI, and human escalation, a Thrive portfolio company. "They're in about 7,000 sites of care today, over 100,000 patients." 00:56:32 Outcomes: "reduce people's hospitalizations by 25%... blood pressure controlled... by over 80%... They save Medicare $2.5 million every week." 00:58:11

Oscar Health

Tech-first health insurer, Thrive's first investment, co-founded by Josh Kushner. "At one point it was down 95%... Now it's back up above its IPO price. I think it's increased 100% year-over-year." 01:05:21

Cityblock Health

Integrated care for high-cost, high-social-need populations, a Thrive portfolio company where Ayogu worked early. "Full-stack... social care, behavioral healthcare, kind of medical care for the patients who need it the most." 00:30:26

Amazon Health (PillPack, Amazon Pharmacy, Amazon Clinic, One Medical)

Ayogu's previous employer. He describes the sequenced strategy of logistics advantage (pharmacy), then virtual transactional care (Clinic), then relational care (One Medical). 00:30:26

Eli Lilly

Pharma company, mentioned for winning GLP-1s through manufacturing and commercial innovation. "Lilly leaned into its manufacturing... LillyDirect." 00:38:14 Also launched Tune Therapeutics with NVIDIA. 01:02:06

Merck (Keytruda and the Moderna cancer vaccine)

Keytruda is described as a checkpoint inhibitor whose "2025 revenue of just that one drug was larger than the revenue of you know, all the major labs combined." 00:35:12 The Merck/Moderna personalized mRNA melanoma vaccine showed "50% less likely to have a recurrence of that cancer in 5 years" in phase 3. 00:37:26

Moderna

Described as "the COVID GOATs of mRNA," partner in the personalized cancer vaccine. 00:36:04

DeepMind, Anthropic

Cited as holding the same AI-researcher talent bar as Isomorphic: "DeepMind and Iso and Anthropic and OpenAI. They all hold the same bar." 00:11:54

Chai

Named as an AI drug discovery company alongside Isomorphic. 00:04:29

Epic

Dominant EHR vendor, used as a benchmark: "Epic took 40 years... less than 50% of physicians." 00:45:39

Butterfly

Handheld ultrasound company, where Fortell's founder previously built hardware. 00:23:33

TSMC

Chip fab used by Fortell for taping out its custom chips. 00:23:33

SpaceX, Tesla (Optimus), NVIDIA

SpaceX and Tesla/Optimus cited as the hardware-talent benchmark for Neuralink: "at the same level of SpaceX and sort of Tesla." 00:14:44 NVIDIA is cited for chips versus the brain's efficiency, and as Lilly's partner. 00:20:53

McKesson

Distributor expanding into care delivery: "McKesson has gone out and bought large oncology providers." 01:03:50

Novo Nordisk

GLP-1 first mover that lost ground on supply. "Novo was first." 00:38:14

Stripe, Google, Oracle

Cited as incumbents moving fast via acquisition and build in the AI era. 01:02:06

Commure

Mentioned by Molly from a prior healthcare conversation. 00:13:48

Thrive portfolio names mentioned by Molly

Nudge was named by Molly among Thrive's healthcare portfolio. 00:03:49

Biohub (Chan Zuckerberg)

Event Molly just attended, featuring Isomorphic Labs on stage. 00:01:48

ARPA-H

Government agency praised for working on clinical-trial efficiency. "Credit to ARPA-H. They've been doing a lot of work recently around thinking about... driving efficiency around that portion." 00:09:03

Penn (Baby KJ treatment), Harvard / Boston Children's

Penn is credited with the custom gene-editing therapy for Baby KJ. 00:51:48 Boston Children's and Harvard hospitals partnered with OpenAI on unsolved pediatric cases. 01:07:52

Podcast sponsors

Brex, Harvey, Turing, Zone, VCX by Fundrise, Public, and Deel appeared as sponsors; Brex and Harvey were named alongside customers like Vercel, OpenAI, Anthropic, Granola, and Deepgram. 00:21:13

4. People Identified

Demis Hassabis

Founder of DeepMind and Isomorphic Labs, Nobel Prize winner. Ayogu: "Demis got the Nobel Prize, is because he created this thing that created this whole field." 00:09:03

Josh Kushner

Thrive Capital founder and Oscar co-founder. Ayogu: "he spent so much time kind of working with Demis, letting them know that we appreciate kind of what they're doing." 00:11:54 Also pursued Isomorphic when Demis wasn't raising (per Molly). 00:11:54

Matt DeJonge

Founder of Fortell, previously at Butterfly. "He'd spent 15 years thinking of this project... He was fairly obsessed with a space that most people aren't obsessed with." 00:23:33

DJ (Neuralink president)

Leads much of Neuralink. "He's a very compelling leader... passion is contagious. I also think excellence and talent density is contagious." 00:19:53

Dan (OpenEvidence founder)

College classmate of Ayogu. Ayogu drove to his house on the strength of the product. 00:44:56

Brad (Lightcap) and Sam (Altman)

OpenAI leaders Ayogu briefed on healthcare and whose leadership he connected to healthcare CEOs. 00:40:11

Steve Martin and Henry Kravis

Fortell beta users and exacting judges of quality. "These are hard judges of what quality is." 00:26:16

Kareem

Thrive co-founder-level colleague Ayogu has known since college. 00:30:26

Mario

Oscar co-founder Ayogu debated early; he joked they should have called Oscar "Elphaba." 01:04:30

Max

Spoke on the Biohub panel and set the 88-90% success-rate goal for drug development (per Molly). 00:08:37

Annie Lamont

Prior Sourcery guest on AI healthcare. 00:13:48

Priscilla Chan and Mark Zuckerberg

Hosted the Biohub event. 00:01:48

5. Operating Insights

Sell the "Bad Tech" Antidote: Win Users by Removing Mandates

Health IT is "like Brussels sprouts... forced to use these tools." 00:44:26 The OpenEvidence insight is to build tools users choose, not tools procurement imposes; voluntary joy is the adoption signal. Ayogu: "people are willfully telling me about something with with joy in their eyes."

Intervene at the Moment of Signal, Not an Hour Later

Cadence's AI calls patients the instant they take a measurement. "I need to call you right when you're taking the blood pressure measurement, because now you're in that mode. And with AI, they can do that." 01:00:17 They report a 70% increase in reaching patients, a general lesson on timing outreach to user intent.

Sequence Expansion by Earned Trust

Amazon's health rollout moved from logistics, to low-acuity transactional care, to relational care, each step earning permission for the next. "People trust you with their medications. Will they trust you with their care delivery?" 00:30:26

Pick the Right Metric Layer in Healthcare Sales

Ayogu's front/back/in-office framing shows where adoption follows money: "People will adopt the tools that will help them make more money very rapidly," so revenue cycle tooling went first, then voice agents in the front office, then in-office tools like scribes and OpenEvidence. 00:43:13

Plan for the Next Bottleneck at the Start

"Often times, you have to plan for the end at the beginning." 00:09:03 In practice, size manufacturing, payer, and clinical capacity alongside the science, as Lilly did.

6. Overlooked Insights

Healthcare Supply Is a Matching Problem AI Can Unlock Without Hiring More Specialists

In a brief aside, Ayogu notes that surgeons "spend half of their time on non-operative cases" while there is a "3-month, 4-month wait for an orthopedic surgeon in LA." 01:08:38 If AI triage and self-service knowledge route only surgical cases to surgeons, capacity expands without a single new hire. That implies large value in scheduling, triage, and routing layers, not just clinical-decision tools, and it's the logic behind his line that the nation needs "a 10x nurse a lot more than we need a 10x engineer." 00:00:53

Hardware Teams From Adjacent Industries Are Becoming Biotech's Secret Weapon

In passing, Ayogu notes Neuralink's hardware talent matches SpaceX and Tesla/Optimus and that building a neurosurgical robot is "one vertical of what they do," while for others it "would be their whole business." 00:14:44 Fortell's team came from Butterfly and tapes out custom silicon on first try. The pattern is that deep-tech hardware operators moving into medicine can vertically integrate (robots, chips, pathology labs) in ways pure biotech and medtech incumbents can't, which suggests a source of defensibility and a sourcing heuristic for investors.